Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Evaluation of theranostic nanocarriers for near-infrared imaging and photodynamic therapy on human prostate cancer cells

Full text
Leandro, Fernanda Z. ; Martins, Julia ; Fontes, Aparecida M. ; Tedesco, Antonio C.
Total Authors: 4
Document type: Journal article
Source: COLLOIDS AND SURFACES B-BIOINTERFACES; v. 154, p. 341-349, JUN 1 2017.
Web of Science Citations: 8

This paper evaluates how effectively chloroaluminum phthalocyanine (ClAlPc) entrapped in colloidal nanocarriers, such as nanocapsule (NC) and nanoemulsion (NE), induces photodamage in human prostate cancer cells (LNCaP) during photodynamic therapy (PDT). The MTT cell viability assay showed that both ClAlPc-NC and ClAlPc-NE induced phototoxicity and efficiently killed LNCaP cells at low ClAlPc-NC and ClAlPc-NE concentrations (0.3 mu g mL(-1)) as well as under low light doses of 4J cm(-2) and 7 J cm(-2), respectively, upon PDT with a 670-nm diode laser line. Confocal imaging studies indicated that ClAlPc-NC and ClAlPc-NE were preferentially localized in the perinuclear region of LNCaP cells both in the dark and upon irradiation with laser light. After PDT treatment, ClAlPc-NC-treated LNCaP cells exhibited a higher green fluorescence signal, possibly due to the larger shrinkage of the actin cytoskeleton, compared to ClAlPc-NE-treated LNCaP cells. Additionally, ClAlPc-NC or ClAlPc-NE and mitochondria showed a relatively high co-localization level. The cellular morphology did not change in the dark, but confocal micrographs recorded after PDT revealed that LNCaP cells treated with ClAlPc-NC or ClAlPc-NE underwent morphological alterations. Our preliminary in vitro studies reinforced the hypothesis that biocompatible theranostic ClAlPc-loaded nanocarriers could act as an attractive photosensitizer system in PDT and could serve as an interesting molecular probe for the early diagnosis of prostate cancer and other carcinomas. (C) 2017 Elsevier B.V. All rights reserved. (AU)

FAPESP's process: 13/50181-1 - Use of drugs containing nanocarriers with photosensitizers and/or other active compounds applied to cell therapy and treatment of central nervous system disorders
Grantee:Antonio Claudio Tedesco
Support type: Research Projects - Thematic Grants
FAPESP's process: 08/53719-4 - Use of nanocarriers containing photosensitive dyes and other derived and growing factors applied to the photodynamic process in the health areas
Grantee:Antonio Claudio Tedesco
Support type: Research Projects - Thematic Grants